World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
68
Citations
22146
World Ranking
2555
National Ranking
14

Esper G. Kallas publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Esper G. Kallas sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 329 publications — 70th percentile

70% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Esper G. Kallas D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Esper G. Kallas sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 68 D-Index — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2021 - Distinguished International Fellow of the American Society of Tropical Medicine and Hygiene (ASTMH)

Overview

Esper G. Kallas is affiliated with the Universidade de São Paulo in Brazil and focuses on medical research with an emphasis on infectious diseases. Their work encompasses a range of subfields including infectious diseases, public health, epidemiology, neurology, and virology. The scientist's research covers various topics such as mosquito-borne diseases and control, SARS-CoV-2 and COVID-19 research, COVID-19 clinical research studies, viral infections and vectors, long-term effects of COVID-19, viral infections and outbreaks research, and HIV/AIDS research and interventions.

Several recent publications by Esper G. Kallas are as follows:

  • Live, Attenuated, Tetravalent Butantan-Dengue Vaccine in Children and Adults, 2024, New England Journal of Medicine
  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women, 2021, New England Journal of Medicine
  • Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial, 2020, Trials
  • Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study, 2021, SSRN Electronic Journal
  • Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial, 2021, Nature Medicine

Frequent co-authors include:

  • Éster Cerdeira Sabino (23 collaborations)
  • Carlos Roberto Ribeiro de Carvalho (16 collaborations)
  • Eloísa Bonfá (15 collaborations)
  • Anna S. Levin (15 collaborations)
  • Cássia Gisele Terrassani Silveira (14 collaborations)

Esper G. Kallas publishes regularly in various venues, including:

  • bioRxiv (Cold Spring Harbor Laboratory) with 16 publications
  • SSRN Electronic Journal with 7 publications
  • Clinics with 4 publications
  • The Journal of Infectious Diseases with 4 publications
  • Vaccine with 4 publications

Their scientific contributions are largely situated within the field of medicine, totaling 272 publications, with a pronounced focus on infectious diseases accounting for 119 publications. The scientist is recognized as a Distinguished International Fellow of the American Society of Tropical Medicine and Hygiene (ASTMH), an award received in 2021.

Best Publications

  • Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men

    Robert M. Grant;Javier R. Lama;Peter L. Anderson;Vanessa McMahan

  • Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study

    Robert M. Grant;Robert M. Grant;Robert M. Grant;Peter L. Anderson;Vanessa McMahan;Albert Liu

  • Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.

    Peter L. Anderson;David V. Glidden;Albert Liu;Susan Buchbinder

  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

    Raphael J Landovitz;Deborah Donnell;Meredith E Clement;Brett Hanscom

  • Circulating Follicular Helper–Like T Cells in Systemic Lupus Erythematosus: Association With Disease Activity

    Jin Young Choi;John Hsi En Ho;Sandra G. Pasoto;Viviane Bunin

  • Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans.

    David I Watkins;Dennis R Burton;Esper G Kallas;John P Moore

  • HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial

    Madeline B Deutsch;David V Glidden;Jae Sevelius;Joanne Keatley

  • Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.

    Ricardo Palacios;Elizabeth González Patiño;Roberta de Oliveira Piorelli;Monica Tilli Reis Pessoa Conde

  • No Evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis

    Julia L. Marcus;David V. Glidden;Kenneth H. Mayer;Albert Y. Liu

  • International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials

    T. Christopher Mast;Lisa Kierstead;Swati B. Gupta;Alexander A. Nikas

  • Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study

    Beatriz Grinsztejn;Brenda Hoagland;Ronaldo I Moreira;Esper G Kallas

  • Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans.

    Alba Grifoni;John Pham;John Sidney;Patrick H O'Rourke

  • Syphilis predicts HIV incidence among men and transgender women who have sex with men in a preexposure prophylaxis trial.

    Marc M. Solomon;Kenneth H. Mayer;Kenneth H. Mayer;David V. Glidden;Albert Y. Liu

  • Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study

    Palacios R;Batista Ap;Albuquerque Csn;Patiño Eg

  • Upregulation of reactive oxygen species generation and phagocytosis, and increased apoptosis in human neutrophils during severe sepsis and septic shock.

    Paulo Sergio Martins;Esper Georges Kallas;Miguel Cendoroglo Neto;Maria Aparecida Dalboni

  • Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.

    Ana C Medeiros-Ribeiro;Nadia E Aikawa;Carla G S Saad;Emily F N Yuki

  • Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis.

    Marc M. Solomon;Javier R. Lama;David V. Glidden;Kathleen Mulligan

  • Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal.

    Fatema A. Legrand;Douglas F. Nixon;Christopher P. Loo;Erika Ono

  • QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

    Thomas G. Evans;M.Juliana McElrath;Tom Matthews;David Montefiori

  • Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes

    Vivek Jain;Maria C. Sucupira;Peter Bacchetti;Wendy Hartogensis

  • Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository

    Reshma Kassanjee;Reshma Kassanjee;Christopher D. Pilcher;Sheila M. Keating;Shelley N. Facente

  • Genealogical evidence for positive selection in the nef gene of HIV-1.

    Paolo M. de A. Zanotto;Esper G. Kallas;Robson F. de Souza;Edward C. Holmes

  • High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project

    Brenda Hoagland;Ronaldo I. Moreira;Raquel B. De Boni;Esper G. Kallas

  • IVIg immune reconstitution treatment alleviates the state of persistent immune activation and suppressed CD4 T cell counts in CVID.

    Dominic Paquin-Proulx;Bianca A. N. Santos;Karina I. Carvalho;Myrthes Toledo-Barros

  • Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease.

    Denise do Socorro da Silva Rodrigues;Eduardo Alexandrino Servolo de Medeiros;Lily Yin Weckx;W. Bonnez

  • Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network.

    Matthew T. Aliota;Leda Bassit;Shelton S. Bradrick;Bryan Cox

  • Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets

    Daniela Weiskopf;Cristhiam Cerpas;Michael A. Angelo;Derek J. Bangs

Frequent Co-Authors

Douglas F. Nixon
Douglas F. Nixon Cornell University
Ester C. Sabino
Ester C. Sabino Universidade de São Paulo
Robert M. Grant
Robert M. Grant University of California, San Francisco
Jorge Kalil
Jorge Kalil Universidade de São Paulo
Michael P. Busch
Michael P. Busch University of California, San Francisco
David I. Watkins
David I. Watkins George Washington University
Alessandro Sette
Alessandro Sette La Jolla Institute For Allergy & Immunology
Mauro Schechter
Mauro Schechter Federal University of Rio de Janeiro
Jeffrey N. Martin
Jeffrey N. Martin University of California, San Francisco
Dennis R. Burton
Dennis R. Burton Scripps Research Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to various healthcare careers, many of which can be pursued through accessible online programs. For those interested in entering nursing with foundational training, exploring easy LPN programs to get into can provide a practical starting point. These programs offer streamlined paths for gaining essential nursing skills in less time.

Building on an LPN foundation, advancing to a Nurse Practitioner role is a common goal. Prospective students can find guidance by reviewing options labeled as the easiest NP program, which balances program rigor with flexibility. This is particularly valuable for working professionals.

Specializing further, psychiatric care remains a rapidly growing field. For those interested in mental health nursing, the top online PMHNP programs with best clinical placement rates offer excellent career prospects and hands-on experience opportunities that help bridge academic learning with clinical practice.

Cost is a critical consideration for many students. To manage expenses, researching the cheapest psych NP programs can make specialized nursing degrees more attainable without compromising quality, ensuring broader access to advanced healthcare careers.

Best Scientists Citing Esper G. Kallas

Trending Scientists

Recently Published Articles